A CRISPR-Cas9 knockout screening identifies IRF2 as a key driver of OAS3/RNase L-mediated RNA decay during viral infection.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
05 Nov 2024
Historique:
medline: 31 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: ppublish

Résumé

OAS-RNase L is a double-stranded RNA-induced antiviral pathway triggered in response to diverse viral infections. Upon activation, OAS-RNase L suppresses virus replication by promoting the decay of host and viral RNAs and inducing translational shutdown. However, whether OASs and RNase L are the only factors involved in this pathway remains unclear. Here, we develop CRISPR-Translate, a FACS-based genome-wide CRISPR-Cas9 knockout screening method that uses translation levels as a readout and identifies IRF2 as a key regulator of OAS3. Mechanistically, we demonstrate that IRF2 promotes basal expression of OAS3 in unstressed cells, allowing a rapid activation of RNase L following viral infection. Furthermore, IRF2 works in concert with the interferon response through STAT2 to further enhance OAS3 expression. We propose that IRF2-induced RNase L is critical in enabling cells to mount a rapid antiviral response immediately after viral infection, serving as the initial line of defense. This rapid response provides host cells the necessary time to activate additional antiviral signaling pathways, forming secondary defense waves.

Identifiants

pubmed: 39475651
doi: 10.1073/pnas.2412725121
doi:

Substances chimiques

2-5A-dependent ribonuclease EC 3.1.26.-
Interferon Regulatory Factor-2 0
Endoribonucleases EC 3.1.-
2',5'-Oligoadenylate Synthetase EC 2.7.7.84
IRF2 protein, human 0
OAS3 protein, human EC 2.7.7.84
RNA, Viral 0
STAT2 Transcription Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2412725121

Subventions

Organisme : HHS | National Institutes of Health (NIH)
ID : R37-CA252081
Organisme : HHS | National Institutes of Health (NIH)
ID : R01-AI155962
Organisme : American Cancer Society (ACS)
ID : RSG-24-1249960-01-DMC

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Sunwoo Oh (S)

Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697.

Gisselle Santiago (G)

Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697.

Lavanya Manjunath (L)

Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697.

Junyi Li (J)

Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697.

Alexis Bouin (A)

Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine, CA 92697.

Bert L Semler (BL)

Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine, CA 92697.

Rémi Buisson (R)

Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH